Keyphrases
Apoptotic Cell Death
100%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
100%
Idasanutlin
100%
Navitoclax
100%
Combination Treatment
37%
Apoptosis
25%
B-cell Lymphoma 2 (Bcl-2)
25%
Tumor Protein p53 (TP53)
25%
Murine Double Minute 2 (MDM2)
25%
Treatment Group
12%
Hematological Malignancies
12%
Specific Inhibitor
12%
Overall Survival
12%
Clinical Setting
12%
Preclinical Data
12%
Xenograft
12%
Highly Active
12%
Tumor Suppressor Activity
12%
Pro-apoptotic
12%
Notch Pathway
12%
Activating mutation
12%
Inactivating mutation
12%
MYC Expression
12%
Acute Lymphoblastic Leukemia Cells
12%
BBC3
12%
Venetoclax
12%
Oncogenic Stress
12%
Synergic
12%
BH3 Mimetics
12%
MDM2 Inhibitor
12%
Bcl-xL Inhibitor
12%
BH3 Domain
12%
MDM2-p53
12%
Medicine and Dentistry
Programmed Cell Death
100%
Acute Lymphoblastic Leukemia
100%
Idasanutlin
100%
Navitoclax
100%
In Vitro
12%
Hematologic Malignancy
12%
Overall Survival
12%
Leukemia Cell
12%
Protein P53
12%
Xenograft
12%
Bcl-xL
12%
Oncogene C Myc
12%
Notch
12%
Venetoclax
12%
Tumor Suppressor Protein
12%
Treatment Group
12%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Idasanutlin
100%
Navitoclax
100%
Hematologic Malignancy
12%
Overall Survival
12%
Protein P53
12%
Tumor Suppressor Protein
12%
Venetoclax
12%
Treatment Group
12%
Neuroscience
T Cell
100%
Programmed Cell Death
100%
Bcl-2
25%
In Vivo
12%
In Vitro
12%
TP53
12%
Notch
12%
P53
12%
Oncogene C Myc
12%
Tumor Suppressor Protein
12%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Programmed Cell Death
100%
Bcl-2
25%
Oncogene C Myc
12%
Overall Survival
12%
P53
12%
Tumor Suppressor Protein
12%
Bcl-xL
12%
Notch
12%